Altimmune (NASDAQ:ALT) Shares Up 5.3%

Altimmune, Inc. (NASDAQ:ALT) traded up 5.3% on Thursday . The company traded as high as $9.38 and last traded at $9.36. 660,352 shares changed hands during trading, a decline of 89% from the average session volume of 5,935,036 shares. The stock had previously closed at $8.89.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. B. Riley reaffirmed a “buy” rating and set a $20.00 price objective on shares of Altimmune in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Altimmune in a report on Friday, December 1st. Finally, The Goldman Sachs Group started coverage on Altimmune in a report on Wednesday, January 24th. They set a “neutral” rating and a $13.00 price objective on the stock.

Altimmune Trading Up 15.2 %

The firm has a market capitalization of $550.20 million, a price-to-earnings ratio of -6.71 and a beta of 0.08. The firm has a fifty day moving average price of $9.92 and a 200 day moving average price of $6.69.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ALT. Osaic Holdings Inc. raised its position in Altimmune by 77.3% in the 2nd quarter. Osaic Holdings Inc. now owns 7,834 shares of the company’s stock worth $28,000 after purchasing an additional 3,416 shares during the last quarter. WealthPlan Investment Management LLC bought a new position in Altimmune in the 3rd quarter worth approximately $31,000. FNY Investment Advisers LLC bought a new position in Altimmune in the 4th quarter worth approximately $35,000. Keudell Morrison Wealth Management bought a new position in Altimmune in the 3rd quarter worth approximately $36,000. Finally, Brave Asset Management Inc. bought a new position in Altimmune in the 3rd quarter worth approximately $39,000. Institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.